ARA-290
10mgVolume Pricing
Per unit — bulk discounts applied automaticallyWholesale pricing available for approved accounts
About ARA-290
ARA-290 (Cibinetide) is a synthetic 11-amino acid peptide derived from the non-erythropoietic tissue-protective structure of erythropoietin (EPO). It selectively activates the innate repair receptor (IRR), a heterodimer of the EPO receptor and the IL-3 receptor beta common chain. ARA-290 is extensively studied for neuroprotection, anti-inflammatory effects, and tissue repair without stimulating erythropoiesis.
Frequently Asked Questions
All Signal peptides undergo rigorous third-party testing and are guaranteed ≥99% purity. Every batch comes with a Certificate of Analysis (COA) verified through AuthentiChain's blockchain verification system.
Orders placed before 12PM EST ship same-day via cold chain logistics. Products are shipped in insulated packaging with dry ice to maintain temperature integrity. Standard delivery is 1–3 business days.
Approved accounts have access to flexible payment terms including NET 30, wire transfer, and credit card. Volume-based pricing is automatically applied at checkout based on your order quantity.
Absolutely. Contact your dedicated account manager or reach out to info@signalpeps.com with the product name and lot number. COAs are also available digitally through our AuthentiChain verification badge on each product page.
Published Study Findings on ARA-290
Detailed Research & Citations
In-depth findings from peer-reviewed preclinical and clinical studies
ARA-290 (Cibinetide) is a synthetic 11-amino acid peptide derived from the tissue-protective structure of erythropoietin (EPO). It selectively activates the innate repair receptor (IRR) — a heterocomplex of the EPO receptor and IL-3 receptor beta common chain (βcR) — without stimulating erythropoiesis. ARA-290 is studied for neuroprotection, anti-inflammatory effects, metabolic regulation, and tissue repair across multiple organ systems.
Innate Repair Receptor Activation
ARA-290 selectively activates the innate repair receptor (IRR), triggering anti-apoptotic and cytoprotective signaling cascades including JAK2/STAT5, PI3K/Akt, and NF-κB modulation. This provides neuroprotection without the erythropoietic side effects of EPO.
Molecular Medicine (2008)Small Fiber Neuropathy Improvement
In a randomized, double-blind, placebo-controlled Phase II trial in sarcoidosis patients with small fiber neuropathy, ARA-290 significantly improved corneal nerve fiber density, neuropathic pain scores, and quality of life measures over 28 days of treatment.
Molecular Medicine (2012)Cytokine & Macrophage Modulation
ARA-290 reduces pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) and shifts macrophage polarization from M1 (pro-inflammatory) to M2 (reparative) phenotype, promoting tissue healing while dampening destructive inflammation.
Molecular Medicine (2008)Glycemic & Metabolic Effects
In Type 2 diabetes studies, ARA-290 improved metabolic parameters including HbA1c, cholesterol levels, and body weight. The metabolic benefits appear mediated through IRR-dependent pathways in pancreatic beta cells and adipose tissue.
Diabetes & Metabolism (2014)Myocardial Ischemia Protection
In preclinical models of myocardial ischemia-reperfusion injury, ARA-290 reduced infarct size by up to 50%, decreased cardiomyocyte apoptosis, and preserved cardiac function through IRR-mediated anti-apoptotic signaling.
Molecular Medicine (2008)Clinical Safety & Tolerability
ARA-290 has demonstrated excellent safety and tolerability across multiple Phase I and Phase II clinical trials. No erythropoietic effects, thromboembolic events, or serious adverse events related to the study drug have been reported. The most common side effects were mild injection site reactions.
Molecular Medicine (2012)View All 3 Sources
- Tissue-protective peptides derived from erythropoietin: their biology and translational potential
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss
- ARA 290, a non-erythropoietic EPO analogue, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
All findings above are sourced from peer-reviewed journals for educational reference. This product is for research purposes only — not for human consumption. Preclinical results may not translate to human outcomes.
Chemical Identity
How to Order
Three simple steps to access premium research peptides
Apply for an Account
Submit a quick application with your business details. Takes less than 2 minutes.
Get Approved
Our team reviews applications within 1–2 business days. You'll receive an email once approved.
Place Your Order
Browse the catalog, select quantities, and checkout. Volume pricing applies automatically.
All products are for research and laboratory purposes only. Not intended for human or animal consumption. Only qualified professionals should handle these products.
